Divis Laboratories Ltd News
CDMO shares under pressure; Neuland, Laurus, Syngene tank up to 12%
Thus far in the calendar year 2024 (CY24), the market price of Neuland Laboratories has zoomed 216%, Piramal Pharma (88%), Divi's Labs (53%) and Jubilant Pharmova (52%)
 "CDMO shares under pressure; Neuland, Laurus, Syngene tank up to 12%")
Divi's Laboratories shares slip 6% in trade; what's worrying investors?
The filing further said that the financials of the company won't be impacted and the penalty will be paid within the prescribed timeline
 "Divi's Laboratories shares slip 6% in trade; what's worrying investors?")
Divi's Labs set for continued growth, valuation may cap upside: Analysts
Shares of Divis's Laboratories scaled up to 3.4 per cent at Rs 6145.60 per share on the BSE after beating street estimates in its second quarter earnings for the financial year 2024-25 (Q2FY25)
 "Divi's Labs set for continued growth, valuation may cap upside: Analysts")
Divis Labs Q2 Preview: Net profit may jump 36%, revenue by 15 YoY%
Brokerages expect Divis Labs to report a robust quarter on a year-on-year basis and sequentially
 "Divis Labs Q2 Preview: Net profit may jump 36%, revenue by 15 YoY%")
Dixon, MCX, Divis Lab: Trading strategies in F&O stocks with high PCR
The PCR (Put Call Ratio) of these 3 stocks is above 1, implying presence of higher open positions in Puts as against Calls, shows the NSE options data.
 "Dixon, MCX, Divis Lab: Trading strategies in F&O stocks with high PCR")
This pharma stock has zoomed 57% thus far in 2024; Citi sees more upside
Divi's Labs share: In the last four days, Divi's Lab share price has surged 13 per cent after global brokerage firm Citi initiated coverage on Divi's Laboratories with a 'Buy' rating
 "This pharma stock has zoomed 57% thus far in 2024; Citi sees more upside")
Divi's Lab, AEL, M&M among top movers & shakers in FY25; trading guide here
Among existing gainers, Divi's Lab and Shriram Finance seem poised for further gains, whereas losers IndusInd Bank and Nestle too look promising on technical charts; check key levels.
 "Divi's Lab, AEL, M&M among top movers & shakers in FY25; trading guide here")
F&O Insights: Will Bank Nifty see short-covering? Check key levels here
Derivatives market update for Sept 11: Bank Nifty weekly options PCR stands at 0.9:1; key trigger point at 51,550. Premium in Bank Nifty futures down to 99 pts from 255 pts in just 3 trading sessions.
 "F&O Insights: Will Bank Nifty see short-covering? Check key levels here")
F&O Insights: IPCA, Divis Lab see bullish bets; 24,700 the key for Nifty
Derivatives market update: 12 stocks including Balrampur Chini, GNFC, India Cement, LIC Housing and National are in F&O ban on Thursday; 2 stocks see buildup up short positions; details here
 "F&O Insights: IPCA, Divis Lab see bullish bets; 24,700 the key for Nifty")
Divi's Labs shares jump 5% as US court stays FDA approval for Entresto drug
Shares of Divi's Laboratories surged up to 5 per cent at Rs 4960 per share on the BSE in Wednesday's intraday deals
 "Divi's Labs shares jump 5% as US court stays FDA approval for Entresto drug")
BSE Healthcare hits new high; rallies 10% in 1 month on strong outlook
Solara Active Pharma Sciences, Indoco Remedies, Dishman Carbogen Amcis, Krishna Institute of Medical Sciences, Divi's Lab, Strides Pharma, Narayana Hrudayalaya and Vijaya Diagnostic were up 5 per cent
 "BSE Healthcare hits new high; rallies 10% in 1 month on strong outlook")
Earnings growth priced-in Divi's Labs stock, niche biz to expand: Analysts
Analysts say pharmaceutical company's stock fully priced in
 "Earnings growth priced-in Divi's Labs stock, niche biz to expand: Analysts")
